Research programme: mGlu2 NAM - Addex Therapeutics
Alternative Names: Metabotropic glutamate receptor 2 modulators - Addex TherapeuticsLatest Information Update: 24 Feb 2025
At a glance
- Originator Addex Therapeutics
- Class Nootropics; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cognition disorders
Most Recent Events
- 24 Feb 2025 Addex Therapeutics plans to initiate clinical candidate selection in Cognition disorders first half of 2025 (Addex Therapeutics pipeline, February 2025)
- 18 Aug 2022 Addex Therapeutics expect to enter IND enabling studies early in H2 2023 (Addex Therapeutics pipeline, August 2022)
- 01 Sep 2021 Preclinical trials in Cognition disorders in Switzerland (PO) (Addex Therapeutics pipeline, September 2021)